iRhythm Technologies, Inc. (IRTC)

116.27 -0.07 (-0.06%) As of 09:39AM EDT. Market open.

iRhythm Technologies, Inc.

699 8th Street
Suite 600
San Francisco, CA 94103
United States
415 632 5700
https://www.irhythmtech.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 2,000

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Quentin S. Blackford	President, CEO & Director	1.42M	N/A	1979
Mr. Brice Bobzien CPA	Chief Financial Officer	715.24k	N/A	1979
Dr. Minang P. Turakhia M.D., M.S.	Chief Medical & Scientific Officer and Executive VP of Product Innovation	749.18k	N/A	1974
Mr. Patrick Michael Murphy J.D.	Chief Business & Legal Officer	766.93k	N/A	1979
Mr. Chad M. Patterson	Chief Commercial Officer	836.55k	N/A	1982
Mr. Mervin Smith	Executive Vice President of Business Operations	N/A	N/A	1975
Mr. Marc Rosenbaum	Senior VP of Finance & Chief Accounting Officer	N/A	N/A	1972
Mr. Mark J. Day Ph.D.	Chief Technology Officer	718.76k	1.28M	1971
Mr. Daniel G. Wilson	Executive VP of Corporate Development & Investor Relations	670.09k	N/A	1982
Mr. Douglas J. Devine	Executive Advisor	800k	N/A	1970

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Corporate governance

iRhythm Technologies, Inc.’s ISS governance QualityScore as of 1 April 2024 is 7. The pillar scores are Audit: 10; Board: 5; Shareholder rights: 6; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.